CL2014000357A1 - Compuesto acido (3s)-3-[4-[[5-[(8-metoxi-3,4-dihidro-2h-quinolin-1-il)metil]-2-tienil]metoxi]fenil]hex-4-inoico; metodo para prepararlo; composicion farmaceutica que lo comprende; compuesto intermediario; y su uso para tratar diabetes. - Google Patents

Compuesto acido (3s)-3-[4-[[5-[(8-metoxi-3,4-dihidro-2h-quinolin-1-il)metil]-2-tienil]metoxi]fenil]hex-4-inoico; metodo para prepararlo; composicion farmaceutica que lo comprende; compuesto intermediario; y su uso para tratar diabetes.

Info

Publication number
CL2014000357A1
CL2014000357A1 CL2014000357A CL2014000357A CL2014000357A1 CL 2014000357 A1 CL2014000357 A1 CL 2014000357A1 CL 2014000357 A CL2014000357 A CL 2014000357A CL 2014000357 A CL2014000357 A CL 2014000357A CL 2014000357 A1 CL2014000357 A1 CL 2014000357A1
Authority
CL
Chile
Prior art keywords
methoxy
quinolin
hex
thienyl
dihydro
Prior art date
Application number
CL2014000357A
Other languages
English (en)
Spanish (es)
Inventor
Chafiq Hamdouchi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46690732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000357(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2014000357A1 publication Critical patent/CL2014000357A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2014000357A 2011-08-17 2014-02-13 Compuesto acido (3s)-3-[4-[[5-[(8-metoxi-3,4-dihidro-2h-quinolin-1-il)metil]-2-tienil]metoxi]fenil]hex-4-inoico; metodo para prepararlo; composicion farmaceutica que lo comprende; compuesto intermediario; y su uso para tratar diabetes. CL2014000357A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161524462P 2011-08-17 2011-08-17

Publications (1)

Publication Number Publication Date
CL2014000357A1 true CL2014000357A1 (es) 2014-09-05

Family

ID=46690732

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000357A CL2014000357A1 (es) 2011-08-17 2014-02-13 Compuesto acido (3s)-3-[4-[[5-[(8-metoxi-3,4-dihidro-2h-quinolin-1-il)metil]-2-tienil]metoxi]fenil]hex-4-inoico; metodo para prepararlo; composicion farmaceutica que lo comprende; compuesto intermediario; y su uso para tratar diabetes.

Country Status (30)

Country Link
US (1) US8431706B2 (enExample)
EP (1) EP2744806B1 (enExample)
JP (1) JP5903162B2 (enExample)
KR (1) KR101570624B1 (enExample)
CN (1) CN103687856B (enExample)
AP (1) AP3589A (enExample)
AR (1) AR087451A1 (enExample)
AU (1) AU2012295372A1 (enExample)
BR (1) BR112014003079A2 (enExample)
CA (1) CA2843474C (enExample)
CL (1) CL2014000357A1 (enExample)
CO (1) CO6880069A2 (enExample)
CR (1) CR20140052A (enExample)
DO (1) DOP2014000018A (enExample)
EA (1) EA022165B1 (enExample)
EC (1) ECSP14013211A (enExample)
ES (1) ES2578165T3 (enExample)
GT (1) GT201400022A (enExample)
IL (1) IL230635A (enExample)
IN (1) IN2014MN00191A (enExample)
MA (1) MA35351B1 (enExample)
MX (1) MX2014001832A (enExample)
PE (1) PE20140831A1 (enExample)
PH (1) PH12014500366A1 (enExample)
SG (1) SG11201401793PA (enExample)
TN (1) TN2014000058A1 (enExample)
TW (1) TWI537262B (enExample)
UA (1) UA110983C2 (enExample)
WO (1) WO2013025424A1 (enExample)
ZA (1) ZA201400705B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105722841A (zh) 2013-11-14 2016-06-29 卡迪拉保健有限公司 新型杂环化合物
WO2015084692A1 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10059667B2 (en) 2014-02-06 2018-08-28 Merck Sharp & Dohme Corp. Antidiabetic compounds
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CN109666027A (zh) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 一类酰胺结构的gpr40激动剂化合物及其用途
DK3737470T5 (da) 2018-01-08 2024-05-27 Celon Pharma Sa 3-phenyl-4-hexynsyrederivater som gpr40-agonister
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
EP3978485B1 (en) 2019-05-31 2026-02-11 Hyundai Pharm Co., Ltd. Novel crystal form of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
TWI751585B (zh) * 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
EP4052790A4 (en) * 2019-10-31 2023-12-27 China Petroleum & Chemical Corporation SUPPORTED CATALYST, PRODUCTION PROCESS THEREOF AND APPLICATION THEREOF
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
KR102699076B1 (ko) * 2021-04-01 2024-08-27 현대약품 주식회사 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도
CN115317484B (zh) * 2022-08-26 2023-07-18 北京箭牧科技有限公司 Ly2922470在制备预防或治疗脑血管疾病或组织缺血再灌注损伤药物中的应用
CN115671105B (zh) * 2022-11-22 2023-10-27 北京箭牧科技有限公司 Ly2922470在制备预防或治疗肾脏疾病药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
JP2004529132A (ja) * 2001-03-27 2004-09-24 アクテリオン ファマシューティカルズ リミテッド 1,2,3,4−テトラヒドロイソキノリン誘導体
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
WO2005087710A1 (ja) * 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
JP4859665B2 (ja) * 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
AR078522A1 (es) * 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes

Also Published As

Publication number Publication date
SG11201401793PA (en) 2014-09-26
UA110983C2 (uk) 2016-03-10
US20130045990A1 (en) 2013-02-21
AR087451A1 (es) 2014-03-26
ES2578165T3 (es) 2016-07-21
JP5903162B2 (ja) 2016-04-13
NZ621248A (en) 2015-08-28
GT201400022A (es) 2015-01-16
TWI537262B (zh) 2016-06-11
CR20140052A (es) 2014-06-20
MA35351B1 (fr) 2014-08-01
EP2744806A1 (en) 2014-06-25
CA2843474C (en) 2015-12-15
ECSP14013211A (es) 2014-03-31
WO2013025424A1 (en) 2013-02-21
CO6880069A2 (es) 2014-02-28
EA201490269A1 (ru) 2014-05-30
PE20140831A1 (es) 2014-07-14
DOP2014000018A (es) 2014-04-15
EA022165B1 (ru) 2015-11-30
CN103687856B (zh) 2015-07-22
CN103687856A (zh) 2014-03-26
IN2014MN00191A (enExample) 2015-08-21
EP2744806B1 (en) 2016-04-27
JP2014521744A (ja) 2014-08-28
TN2014000058A1 (en) 2015-07-01
ZA201400705B (en) 2015-11-25
CA2843474A1 (en) 2013-02-21
US8431706B2 (en) 2013-04-30
AP3589A (en) 2016-02-15
PH12014500366A1 (en) 2014-04-14
IL230635A (en) 2015-11-30
TW201319060A (zh) 2013-05-16
IL230635A0 (en) 2014-03-31
KR101570624B1 (ko) 2015-11-19
AU2012295372A1 (en) 2014-01-23
MX2014001832A (es) 2014-02-27
AP2014007436A0 (en) 2014-02-28
BR112014003079A2 (pt) 2017-02-21
KR20140041835A (ko) 2014-04-04

Similar Documents

Publication Publication Date Title
CL2014000183A1 (es) Formulación farmacéutica que contienen anticuerpos anti-pcsk9; metodo para preparar dicha formulación.
BR112013030163A2 (pt) composto, uso cosmético de pelo menos um composto, composição farmacêutica ou cosmética e processo para preparar um composto.
DK3685835T3 (da) Farmaceutiske sammensætninger, der omfatter derivater af perillylalkohol
EP2769976B8 (en) Hydroxamic acid compound containing quinolyl and preparation method thereof, and pharmaceutical composition containing this compound and use thereof
BR112013014692A2 (pt) composto e respectivo processo de preparação e composição farmacêutica
BR112012005853A2 (pt) aplicador automático para preparações farmacêuticas líquidas, particularmente para insulina
BR112014011671A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
BR112014015294A8 (pt) método cosmétido; de referência de cor, especialmente para implementar método; sistema para implementar o metodo, pacote de software de computador para implementar o método
BR112013019623A2 (pt) arquitetura de gerenciamento de propriedade para redes de fornecimento de conteúdo
BR112014007645A2 (pt) composto heterocíclico, métodos para a preparação de um composto heterocíclico, e, composição farmacêutica
LT3623481T (lt) Kompozicijos, skirtos nukleorūgščių sekoskaitai
BR112013013076A2 (pt) Método para operar elevadores
BR112014007134A2 (pt) usos de um composto da fórmula (b), compostos, composição farmacêutica, método de preparação do composto e uso de uma quantidade efetiva de um composto
BR112014013760A2 (pt) composto, composição farmacêutica e uso de um composto
CL2013003129A1 (es) Composicion herbicida de emulsión de aceite en agua, estable de alta resistencia; metodo para preparar dicha composicion.
PE20140831A1 (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina util para el tratamiento de diabetes
EP2654736A4 (en) NEW PHARMACEUTICAL COMPOSITION
BR112013033464A2 (pt) composto, acetato, composição farmacêutica, combinação farmacêutica, método e método melhorado
BR112013008008A2 (pt) composto, composição farmacêutica e processo para preparar um composto
BR112014005669A2 (pt) composto, composição farmacêutica e uso de um composto
BR112014003567A2 (pt) composto, uso de um composto, e, composição farmacêutica
BR112014006420A2 (pt) compostos, composição farmacêutica, uso de um composto e mètodo para o tratamento ou profilaxia
BR112014009950A2 (pt) composto dissubstituído, compostos e composição farmacêutica
EP2702989A4 (en) STABLE PHARMACEUTICAL COMPOSITION
CL2014000328A1 (es) Metodo para preparar composicion que contiene un portador de oxigeno termoestable; composicion farmacéutica que comprende hemoglobina.